| Literature DB >> 35770188 |
Jingwei Lu1, Li Jiang1, Yixuan Chen1, Kexin Lyu1, Bin Zhu1, Yujie Li1, Xueli Liu1, Xinyue Liu1, Longhai Long2, Xiaoqiang Wang2, Houping Xu2, Dingxuan Wang1, Sen Li2.
Abstract
Tendon injury is a disorder of the musculoskeletal system caused by overuse or trauma, which is characterized by pain and limitations in joint function. Since tendon healing is slowly and various treatments are generally ineffective, it remains a clinically challenging problem. Recent evidences suggest that basic fibroblast growth factor (bFGF) not only plays an important role in tendon healing, but also shows a positive effect in laboratory experimentations. The purpose of this review is to summarize the effects of bFGF in the tendon healing. Firstly, during the inflammatory phase, bFGF stimulates the proliferation and differentiation of vascular endothelial cells to foster neovascularization. Furthermore, bFGF enhances the production of pro-inflammatory factors during the early phase of tendon healing, thereby accelerating the inflammatory response. Secondly, the cell proliferation phase is accompanied by the synthesis of a large number of extracellular matrix components. bFGF speeds up tendon healing by stimulating fibroblasts to secrete type III collagen. Lastly, the remodeling phase is characterized by the transition from type III collagen to type I collagen, which can be promoted by bFGF. However, excessive injection of bFGF can cause tendon adhesions as well as scar tissue formation. In future studies, we need to explore further applications of bFGF in the tendon healing process.Entities:
Keywords: basic fiboblast growth factor; mechanism; tendon healing; tendon injury; tendon repair
Year: 2022 PMID: 35770188 PMCID: PMC9234302 DOI: 10.3389/fphys.2022.852795
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.755
FIGURE 1Article Retrieval Flow Chart with inclusion and exclusion process.
Summary of results and characteristics of the studies which investigated the effects of bFGF in tendon healing.
| Study | Animal type | Models establish | Dosage | Time post operation | Outcome | Conclusion |
|---|---|---|---|---|---|---|
|
| Sprague Dawley rats | Patellar tenotomy | bFGF: 0, 10, 100, 1000 ng/ml | 1, 2 weeks | Type III collagen↑ ultimate stress n.a | The injection of bFGF promotes cell proliferation and the synthesis of type III collagen in the early stage of tendon healing, but without improving ultimate strength |
| Number of cells↑ | ||||||
|
| New Zealand rabbits | SDFT tenotomy and repair | Human recombinant bFGF: 1200 ng/kg | 3, 7, 10 days | collagen fibrils diameter↑Biomechanical properties↑Clinical observations↑ | Administration of human recombinant bFGF can significantly enhance the structural and biomechanical of tendon, and prevent tendon adhesion |
|
| Mongrel dogs | flexor tendon transection and repair | bFGF:either 500 ng (1.25 mg/ml) | 21 days | Blood vessel | Administration of bFGF leads to increased tendon cellularity and matrix synthesis. But did not improve the mechanical properties of the tendon |
| or 1000 ng (2.5 mg/ml) | Density↑cellularity↑ratio of type-I collagen to type-III collagen↓tensile mechanical properties n.a | |||||
|
| white leghorn chickens | FDP tenotomy and repair | bFGF: 2 × 109viral particles | 2, 4, 8, 12 weeks | Ultimate Strength↑strength of tendons↑gliding function↑grading of adhesions↓ | AAV2-bFGF improved healing strength without aggravating |
| adhesion formation after tendon injury | ||||||
|
| Japanese white rabbits | left FDFT tenotomy and repair | bFGF: 400 μg/ml | 1, 3, 6 weeks | mechanical strength↑collagen | This bFGF-coated nylon suture induced an increase of biomechanical strength and accelerated cellular proliferation |
| and proliferation of tenocytes↑ | ||||||
|
|
| Tenocytes of rat intrasynovial tendons | AAV2-bFGF | 10 days | Type I collagen↑Type IIIcollagen↑ | Delivery of exogenous bFGF gene to tenocytes can increase significantly the levels of expression of the bFGF and type I and III collagen genes |
| Cell proliferation↑ | ||||||
|
| New Zealand white rabbit | DFTP transection and repair | NA | 1, 3, 7, 14, 28, 56 days | Vascular numbers ↑ | bFGF can promote angiogenesis in the early stage of tendon healing |
|
| Adult male Sprague-Dawley rats | supraspinatus tendon transection and repair | gelatin hydrogel | 2, 4, 6, 8, 12 weeks | MSCs↑biomechanical strength↑fibrovascular scarring↓Scx↑collagen fibers↑ | Administration of FGF-2 stimulated the growth of fibroblastic progenitor cells, resulting in biomechanical and histological improvements of the repaired RC |
| sheets containing recombinant human FGF-2: 5 µg | ||||||
|
| white Leghorn chick-ens | FDP tenotomy and repair | bFGF: 2 × 109viral particles | 2, 3, 4, 5, 6, 7, 8 weeks | TGFβ↑VEGF↑CTGF↑ PDGF n.a type I collagen↑ | Introduction of the FGF-2 gene will lead to the expression of other growth factor genes, thus promoting tendon repair |
|
| adult mongrel ca-nines | ACL laceration and repair | recombinant human bFGF: 10 µg | 1, 3, 6, 24 weeks | The number of newly formed vessels ↑granulation tissue↑ | the application of a bFGF-impregnated |
| pellet seems to enhance the healing potential of the par-tially lacerated ACL |
↑, significant increase; ↓, significant decrease.
n.a, not affected, NA, not applicable; VEGF, vascular endothelial growth factor; CTGF, connective tissue growth factor; TGF-β, transforming growth factor-β; PDGF, platelet-derived growth factor; bFGF, Basic fibroblast growth factor; FDP, flexor digitorum profundus; AAV2, adeno-associated viral type-2; SH, sodium hyaluronate; MCL, mean color level; RC, rotator cuff; Scx, Scleraxis; MSCs, mesenchymal stem cells.
FIGURE 2Mechanisms of the role of bFGF in the process of tendon healing. bFGF promotes angiogenesis, TSCs and tendon cell proliferation, as well as collagen production, thereby promoting tendon repair. bFGF, Basic fibroblast growth factor; VEGF, vascular endothelial growth factor; TSCs, tendon stem cells.
The role of inflammatory mediators and immune cells in tendon injury IL-1β, Interleukin-1β; TNF-α, tumor necrosis factor-α; PGE2, prostaglandin E2.
| Name | Functions |
|---|---|
| IL-1β | • IL-1β produce pro-inflammatory factors and promote the degradation of ECM |
| TNF-α | • Stimulates the production of pro- and anti-inflammatory factors by tenocytes, while matrix metalloproteinases can be produced |
| Macrophages | • M1 macrophages promote inflammatory responses |
| • M2 macrophages dampen the inflammatory response and stimulate neovascularization | |
| Mast cells | • Release of mediators to activate immune cells and promote neovascularization |
| PGE2 | • Regulation of matrix metalloproteinase secretion, inhibiting inflammatory response, causes pain and promotion of angiogenesis |
FIGURE 3Mechanism of action for bFGF in tendon stem cells, mesenchymal stem cells, and fibroblasts. bFGF, Basic fibroblast growth factor; TSC, tendon stem/progenitor cell; TGF-β, transforming growth factor beta; CTGF, Connective tissue growth factor; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor.